Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why [Yahoo! Finance]
Enlivex Therapeutics Ltd. - Ordinary Shares (ENLV)
Company Research
Source: Yahoo! Finance
Enlivex designed Allocetra to reprogram macrophages into their homeostatic state. The therapy is being evaluated in a mid-stage study for treating organ failure associated with sepsis. In the past week, the company's stock lost 51.2%. This downside came after management came out with mixed results from the phase II study evaluating Allocetra over 28 days in patients with sepsis caused by pneumonia, biliary, urinary tract, or peritoneal infections. A stand-alone analysis of Allocetra-treated patients demonstrated substantial reductions in sequential organ failure assessment (SOFA) scores, the primary endpoint of the study. Per management, the treatment appeared most effective in the urinary tract infection (UTI) cohort, resulting in a 90% reduction in SOFA scores, compared to 68% for pneumonia-associated sepsis patients and 36% in patients whose infection source was internal abdomen. Data from the study also showed a reduction in overall mortality rate by 65% in patients treated
Show less
Read more
Impact Snapshot
Event Time:
ENLV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENLV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENLV alerts
High impacting Enlivex Therapeutics Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ENLV
News
- Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events [Yahoo! Finance]Yahoo! Finance
- Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent EventsGlobeNewswire
- Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee OsteoarthritisGlobeNewswire
- Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis [Yahoo! Finance]Yahoo! Finance
ENLV
Analyst Actions
- 4/23/24 - HC Wainwright
ENLV
Sec Filings
- 4/29/24 - Form 6-K
- 4/22/24 - Form 6-K
- 4/16/24 - Form 6-K
- ENLV's page on the SEC website